3-氮杂双环(3.2.2)壬烷 | 283-24-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 中文名称: 3-氮杂双环(3.2.2)壬烷
• 中文别名: 3-氮杂双环[3,2,2]壬烷；三乙基二胺；3-氮杂双环[3.2.2]壬烷；1,4-二氮杂二环[2.2.2]辛烷；3 -氮杂双环[3.2.2]壬烷
• 英文名称: 3-azabicyclo[3,2,2]nonane
• 英文别名: N-3-azabicyclo[3.2.2]nonane；3-Azabicyclo[3.2.2]nonane
• CAS: 283-24-9
• 化学式: C₈H₁₅N
• mdl: MFCD09029040
• 分子量: 125.214
• InChiKey: LICHZOBEUWVYSY-UHFFFAOYSA-N

物化性质

• 熔点：
  163°C
• 沸点：
  222.71°C (rough estimate)
• 密度：
  0.9108 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险等级：
  8
• 海关编码：
  2933990090
• 包装等级：
  II
• 危险品运输编号：
  UN 2921

SDS

Name:	3-Azabicyclo3.2.2nonane 99+% (gc) Material Safety Data Sheet
Synonym:	None known
CAS:	283-24-9

Section 1 - Chemical Product MSDS Name:3-Azabicyclo3.2.2nonane 99+% (gc) Material Safety Data Sheet
Synonym:None known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
283-24-9	3-Azabicyclo3.2.2-Nonane	>99	unlisted

Hazard Symbols: None Listed.
Risk Phrases: 10

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Flammable.
Potential Health Effects
Eye:
May cause eye irritation. May cause chemical conjunctivitis and corneal damage.
Skin:
May cause irritation and dermatitis. May cause cyanosis of the extremities.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. The toxicological properties of this substance have not been fully investigated. Ingestion of large amounts may cause CNS depression.
Inhalation:
The toxicological properties of this substance have not been fully investigated. Aspiration may lead to pulmonary edema. Vapors may cause dizziness or suffocation. May cause burning sensation in the chest.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. Vapors can travel to a source of ignition and flash back. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Will burn if involved in a fire. Use water spray to keep fire-exposed containers cool. Containers may explode in the heat of a fire. Flammable solid.
Extinguishing Media:
For small fires, use dry chemical, carbon dioxide, water spray or alcohol-resistant foam. For large fires, use water spray, fog, or alcohol-resistant foam. Use water spray to cool fire-exposed containers. Water may be ineffective. Do NOT use straight streams of water.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Remove all sources of ignition. Use a spark-proof tool. Provide ventilation. A vapor suppressing foam may be used to reduce vapors.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Ground and bond containers when transferring material. Use spark-proof tools and explosion proof equipment. Avoid contact with eyes, skin, and clothing. Empty containers retain product residue, (liquid and/or vapor), and can be dangerous. Keep container tightly closed. Keep away from heat, sparks and flame. Avoid ingestion and inhalation. Do not pressurize, cut, weld, braze, solder, drill, grind, or expose empty containers to heat, sparks or open flames.
Storage:
Keep away from heat, sparks, and flame. Keep away from sources of ignition. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Flammables-area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate general or local explosion-proof ventilation to keep airborne levels to acceptable levels.
Exposure Limits CAS# 283-24-9: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystalline powder
Color: off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Sublimes
Freezing/Melting Point: 163 deg C
Autoignition Temperature: Not available.
Flash Point: 63 deg C ( 145.40 deg F)
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H15N
Molecular Weight: 125.21

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, ignition sources, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Strong oxidizing agents, strong acids.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 283-24-9: CL5447500 LD50/LC50:
Not available.
Carcinogenicity:
3-Azabicyclo3.2.2-Nonane - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
R 10 Flammable.
Safety Phrases:
S 9 Keep container in a well-ventilated place.
S 16 Keep away from sources of ignition - No
smoking.
S 28A After contact with skin, wash immediately with
plenty of water.
S 33 Take precautionary measures against static
discharges.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 283-24-9: No information available.
Canada
CAS# 283-24-9 is listed on Canada's NDSL List.
CAS# 283-24-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 283-24-9 is listed on the TSCA inventory.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

类别：有毒物品

• 毒性分级：高毒
• 急性毒性：静脉-小鼠 LD50 为 56 毫克/公斤
• 可燃性危险特性：可燃；燃烧时产生刺激烟雾
• 储运特性：通风、低温干燥；与库房食品原料分开存放
• 灭火剂：干粉、泡沫、沙土、二氧化碳、雾状水

反应信息

• 作为反应物：
  描述：

  3-氮杂双环(3.2.2)壬烷 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.17h， 生成
  参考文献：
  名称：

  WO2007/115935

  摘要：

  公开号：
• 作为产物：
  描述：

  Tri(propan-2-yl)silyl 3-azabicyclo[3.2.2]nonane-3-carboxylate 在 四丁基氟化铵 作用下， 以 四氢呋喃 为溶剂， 以94%的产率得到3-氮杂双环(3.2.2)壬烷
  参考文献：
  名称：

  Triisopropylsilyloxycarbonyl (“Tsoc”):  A New Protecting Group for 1^° and 2^° Amines

  摘要：

  DOI：

  10.1021/jo990272o

文献信息

• Pyridazines. 63. Novel thiosemicarbazones derived from formyl- and acyldiazines: synthesis, effects on cell proliferation, and synergism with antiviral agents
  作者：Johnny Easmon、Gottfried Heinisch、Wolfgang Holzer、Brigitte Rosenwirth

  DOI：10.1021/jm00095a027

  日期：1992.8

  with the above mentioned antiviral drugs. Our results do not support the previously expressed opinion that TSC's are selective antiviral agents. In our test systems no evidence for inhibition of virus-induced cytopathic effect was obtained. The TSC derivatives exhibited a broad range of cytotoxic effects, some at concentrations considerably below those reported to have antiviral efficacy. Several of our

  衍生自各种烷基二嗪基（3-哒嗪基，4-嘧啶基，2-吡嗪基）酮和3-哒嗪甲醛的一系列新型硫代半咔唑（TSC）的合成及其对单纯疱疹病毒（HSV）和人类免疫缺陷病毒（HIV）的评估）以及确定其细胞毒性的方法。此外，还研究了这种TSC与著名的抗病毒药无环鸟苷（ACV）和3'-叠氮基3'-脱氧胸苷（AZT）联合使用的效果。在我们的实验条件下，即确定病毒对HSV-1感染HUT78细胞和MT-1细胞感染HIV-1的细胞病变作用，任何TSC都无法检测到抗病毒活性。然而，观察到了对这些快速生长的T4淋巴细胞细胞系增殖的显着影响。可以建立关于这些细胞毒性作用的明确的结构-活性关系：与吡啶，吡嗪或嘧啶衍生的TSC相比，所研究的大多数3-哒嗪基同类物的细胞毒性较小；在这些化合物中将甲基引入哒嗪系统的C-6或延长酰基部分基本上没有影响；所有带有N，N-二甲基氨基或环氨基取代基的化合物的毒性要比带有NH 2或NHR取
• Novel antimalarial 3-azabicyclo[3.2.2]nonane derivatives
  申请人：University of Graz

  公开号：EP2301627A1

  公开（公告）日：2011-03-30

  The present invention relates to novel 3-azabicyclo[3.2.2]nonane derivatives of the general formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined in the specification. The novel 3-azabicyclo[3.2.2]nonane derivatives are particularly useful for treatment and prevention of malaria and trypanosomiasis.

  本发明涉及一般式(I)的新型3-氮杂双环[3.2.2]壬烷衍生物 或其药学上可接受的盐 其中R1、R2、R3、R4、R5、R6、R7、R8、R9和R10如规范中所定义。这些新型3-氮杂双环[3.2.2]壬烷衍生物特别适用于治疗和预防疟疾和锥虫病。
• ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF
  申请人：NOVARTIS AG

  公开号：US20180271837A1

  公开（公告）日：2018-09-27

  A compound of Formula (I)) or or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating hearing loss or balance disorder: wherein R 1 through R 3 , and L are as defined herein.

  提供了一种具有治疗听力丧失或平衡紊乱作用的化合物（I）的药物可接受盐，其中R1至R3和L如本文所定义。
• Discovery of an Orally Active Series of Isoxazoline Glycoprotein IIb/IIIa Antagonists
  作者：Chu-Biao Xue、John Wityak、Thais M. Sielecki、Donald J. Pinto、Douglas G. Batt、Gary A. Cain、Michael Sworin、Arlene L. Rockwell、John J. Roderick、Shuaige Wang、Michael J. Orwat、William E. Frietze、Lori L. Bostrom、Jie Liu、C. Anne Higley、F. Wayne Rankin、A. Ewa Tobin、George Emmett、George K. Lalka、Jean Y. Sze、Susan V. Di Meo、Shaker A. Mousa、Martin J. Thoolen、Adrienne L. Racanelli、Elizabeth A. Hausner、Thomas M. Reilly、William F. DeGrado、Ruth R. Wexler、Richard E. Olson

  DOI：10.1021/jm960799i

  日期：1997.6.1

  Using isoxazoline XR299 (1a) as a starting point for the design of highly potent, long-duration GPIIb/IIIa antagonists, the effect of placing lipophilic substituents at positions alpha and beta to the carboxylate moiety was evaluated. Of the compounds studied, it was found that the n-butyl carbamate 24u exhibited superior potency and duration of ex vivo antiplatelet effects in dogs. Replacement of

  使用异恶唑啉XR299（1a）作为设计高效，长效GPIIb / IIIa拮抗剂的起点，评估了将亲脂性取代基置于羧酸酯部分的α和β处的效果。在所研究的化合物中，发现氨基甲酸正丁酯24u在狗中表现出优异的效力和离体抗血小板作用的持续时间。用可替代的碱性基团取代苯并胺丁-4-基部分，消除异恶唑啉立体中心，并改变异恶唑啉环的方向，导致效力和/或作用时间降低。
• Thrombin inhibitors. 2. Amide derivatives of N.alpha.-substituted L-arginine
  作者：Ryoji Kikumoto、Yoshikuni Tamao、Kazuo Ohkubo、Tohru Tezuka、Shinji Tonomura、Shosuke Okamoto、Yoshinori Funahara、Akiko Hijikata

  DOI：10.1021/jm00182a004

  日期：1980.8

  with tetralin or an oxygen-containing heterocyclic compound as a N alpha-substituent showed an inhibition with an I50 less than 10(-5) M. N-Monosubstituted derivatives of N alpha-dansyl-L-arginine amide were not hydrolyzed at all by thrombin and were hydrolyzed very slowly by trypsin, and N,N-disubstituted derivatives were not hydrolyzed at all by both enzymes.

  制备了一系列具有取代或未取代的萘和杂环化合物作为Nα取代基的Nα-（芳基磺酰基）-L-精氨酸酰胺衍生物，并测试了它们作为凝血酶凝血活性的抑制剂。Nα-丹磺酰基-L-精氨酸酰胺的Nn-丁基和Nn-丁基-N-甲基衍生物对Nα-丹磺酰基-L-精氨酸酰胺的N-烷基和N，N-二烷基衍生物的抑制作用最大。它们的抑制作用与I50为2 X 10（-6）M的Nα-丹磺酰基-L-精氨酸-正丁酯的抑制作用一样。Nα-取代的4-甲基萘他磺酰基-L-精氨酸酰胺衍生物-和4-乙基哌啶也显示出有效的抑制作用，I50为10（-7）至10（-6）M。在该研究中，最有效的抑制作用是1- [Nα-（4,6-二甲氧基萘-2-磺酰基]-精氨酰基] -4-甲基哌啶，I50为7。

表征谱图